Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART
Publicated to:REVISTA ESPANOLA DE CARDIOLOGIA. 70 (6): 444-450 - 2017-06-01 70(6), DOI: 10.1016/j.recesp.2016.10.012
Authors: Saltijeral Cerezo, Adriana; Pérez de Isla, Leopoldo; Alonso, Rodrigo; Muñiz Grijalvo, Ovidio; Díaz Díaz, José Luis; Mata Pariente, Nelva; Andrés Cañas, Raimundo; Díaz Soto, Gonzalo; Pastor Rosado, José; Pinilla Alemán, Jose Miguel; Zambón, Daniel; Pintó Sala, Xavier; Badimon Maestro, Lina; Mata López, Pedro; Fuentes Jiménez, Francisco
Affiliations
Abstract
© 2016 Sociedad Española de Cardiología Introduction and objectives Little is known about the characteristics of persons with familial hypercholesterolemia (FH) younger than 18 years, the lipid-lowering therapy used in these patients, and the lipid goals reached in real life. Our aim was to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients younger than 18 years enrolled in a large national registry. Methods We analyzed patients younger than 18 years enrolled in a large ongoing registry of molecularly-defined patients with FH in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was analyzed in relation to the use of lipid-lowering therapy. Results We enrolled 392 individuals younger than 18 years. Of these, 217 were molecularly-diagnosed FH patients and had a complete follow-up. The median follow-up time was 4.69 years (interquartile range, 2.48-6.38 years), 68.2% of FH patients were on statins, and 41.5% patients had LDL-C < 130 mg/dL. Statin use was the only predictor of LDL-C goal attainment. Conclusions This study shows that a high proportion of FH patients younger than 18 years have high LDL-C levels and fail to achieve recommended LDL-C targets. Statin use was the only independent predictor of LDL-C goal achievement. No safety concerns were detected during follow-up. These results indicate that many FH patients are not adequately controlled and that there is still room for treatment improvement. Full English text available from: www.revespcardiol.org/en
Keywords
Quality index
Bibliometric impact. Analysis of the contribution and dissemination channel
The work has been published in the journal REVISTA ESPANOLA DE CARDIOLOGIA due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2017, it was in position 26/128, thus managing to position itself as a Q1 (Primer Cuartil), in the category Cardiac & Cardiovascular Systems.
From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 7.44, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)
This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:
- Field Citation Ratio (FCR) from Dimensions: 13 (source consulted: Dimensions Aug 2025)
Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-11, the following number of citations:
- Scopus: 32
Impact and social visibility
Leadership analysis of institutional authors
This work has been carried out with international collaboration, specifically with researchers from: Chile.